Colloidal suspensions comprising a therapeutic agent and squalene
Colloidal suspensions comprising a therapeutic agent and squalene. Squalene binds to certain compounds, such as gacyclidine, much more tightly than other drug carriers, such as polylactic glycolic acid. Including squalene in the particulate phase sequesters the therapeutic agent and provides superior stability at room or body temperature.
1. A colloidal aqueous suspension, comprising nanoparticles that comprise squalene and a therapeutic agent selected from the group consisting of a phencyclidine analog, ifenprodil, traxoprodil, (±)-(R,S)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propanol, and carbamathione.
2. The colloidal suspension of claim 1 , wherein the therapeutic agent is a phenycyclidine analog and the phenycyclidine analog is selected from the group consisting of gacyclidine and ketamine.
3. The colloidal suspension of claim 1 , further comprising an amphipathic excipient.